Bharat Biotech has completed the third clinical trial of Corona's BBV-154 Intranasal Vaccine. This vaccine can be given as a booster dose. Bharat Biotech will be given through the nose (Nasal Corona Vaccine). Testing was done at 9 places across the country for the booster dose.
New Delhi: On the occasion of Independence Day, the country has got a big achievement in the war against Corona. In fact, Bharat Biotech has completed the third clinical trial of Corona’s BBV-154 intranasal vaccine. This vaccine can be given as a booster dose.
According to the information, the first and second clinical trials of BBV-154 intranasal vaccine were conducted. During the trial, the vaccine was given as the first and second doses. After successful testing, it was also tested as a booster dose. However, the booster dose was given to those people who had got both the vaccines of Covid.
Bharat Biotech completes clinical development for phase III trials and booster doses for BBV154 intranasal covid vaccine.#BharatBiotech #covid19vaccine #bbv154 #intranasalvaccine #covid19 pic.twitter.com/oh76drnezz
— BharatBiotech (@BharatBiotech) August 15, 2022
The data of both the human clinical trials of Phase III have been sent to the National Regulatory Authorities for approval. Several levels were tested during the first dose trial. During this every aspect of safety and immunogenicity was carefully checked. Along with this it was compared with COVAXINÒ. Bharat Biotech conducted trials at 14 locations across India.
The company had said that the vaccine dose given to healthy volunteers in the first phase of clinical trials worked well. No serious adverse events have been reported. The vaccine was found to be safe, immunogenic and well-functioning in pre-clinical toxicity studies.
The booster dose of Intra Nasal Vaccine was tested at 9 locations. Bharat Biotech will be given through the nose (Nasal Corona Vaccine).
“On this 75th Independence Day, we are proud to announce successful completion of clinical trials for BBV154 intranasal vaccine. We stay committed and focused on innovation and product development; this is yet another achievement for the multidisciplinary teams at Bharat Biotech. If approved, this intranasal vaccine will make it easier to deploy in mass immunization campaigns with an easy to administer formulation and delivery device. Vectored vaccines also enable faster development of targeted vaccines in response to emerging variants of concern. We hereby thank the volunteers, principle investigators, and clinical trial personnel for all their efforts,” Suchitra K. Ella, Joint Managing Director, Bharat Biotech, said in a statement.